Literature DB >> 16368371

Consequences of delayed surgical closure of patent ductus arteriosus in very premature infants.

Sophie Jaillard1, Benoît Larrue, Thameur Rakza, Eric Magnenant, Henri Warembourg, Laurent Storme.   

Abstract

BACKGROUND: Surgical closure of ductus arteriosus is commonly indicated in premature newborns. The aim of this study was to assess short-term and mid-term effects of delayed surgical closure of the ductus arteriosus on respiratory and digestive outcome in extremely preterm infants.
METHODS: We retrospectively studied 58 infants less than 28 weeks gestational age who underwent surgical closure of ductus arteriosus between January 1997 and December 2002. Nine infants with intrauterine growth restriction and major congenital malformation were excluded from the study. Criteria for surgical closure of ductus arteriosus were: (1) medical treatment failure (ie, indomethacin or ibuprofen) and (2) hemodynamically patent ductus arteriosus: systemic arterial pressure less than gestational age in mm Hg, heart failure, left atrial-aortic root ratio greater than 1.6, mean velocity in the left pulmonary artery greater than 0.6 m/s, and ductus arteriosus diameter greater than 3 mm. Infants were divided into two groups: (1) the early group who had surgery before 21 days of life (n = 31), and (2) the late group who had surgery after 21 days of life (n = 27). Preoperative and postoperative criteria were compared between the two groups (ie, gestational age, birth weight, hemodynamic, ventilatory, and echographic [left atrial-aortic root ratio, mean velocity in the left pulmonary artery] parameters).
RESULTS: Preoperative gestational age and birth weight did not differ between the two groups. In the early group, gestational age was 26 weeks (range, 23 to 28 weeks and birth weight was 800 g (range, 630 to 1,240 g). In the late group, gestational age was 26 weeks (range, 24 to 28 weeks) and birth weight was 840 g (530 to 1,130 g). Hemodynamic, ventilatory, and echographic parameters were similar in both groups. Rate of bronchopulmonary dysplasia was similar in both groups. However, at 24 hours post surgery, median FiO2 was higher in the late group (28% [range, 21% to 65%]) than in early group (21% [range, 21% to 60%]) (p < 0.05). Furthermore, full oral feeding was acquired later in the late group (57 days of life [range, 30 to 136 days]) than in the early group (37 days of life [range, 27 to 84 days]) (p < 0.01), and body weight at 36 weeks of post-conceptional age was higher in the early group at 1,800 g (range, 1,250 to 2,750 g) than in the late group at 1,607 g (1,274 to 2,200 g) (p < 0.05).
CONCLUSIONS: Our findings show that early surgical closure of the ductus arteriosus (< 3 weeks of life) is associated with shortened delay for full oral feeding and improved body growth when compared with late surgical closure (> 3 weeks of life).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16368371     DOI: 10.1016/j.athoracsur.2005.03.141

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  12 in total

1.  Results from extrapleural clipping of a patent ductus arteriosus in seriously ill preterm infants.

Authors:  Orhan Demirturk; Murat Güvener; Isa Coşkun; Hüseyin Ali Tünel
Journal:  Pediatr Cardiol       Date:  2011-07-14       Impact factor: 1.655

2.  Late morbidity during childhood and adolescence in previously premature neonates after patent ductus arteriosus closure.

Authors:  Ali Dodge-Khatami; Scott Tschuppert; Bea Latal; Valentin Rousson; Carsten Doell
Journal:  Pediatr Cardiol       Date:  2009-05-02       Impact factor: 1.655

3.  Ibuprofen treatment for closure of patent ductus arteriosus is not associated with increased risk of neuropathology.

Authors:  Michelle Loeliger; Amy Shields; Donald McCurnin; Ronald I Clyman; Bradley Yoder; Terrie E Inder; Sandra M Rees
Journal:  Pediatr Res       Date:  2010-10       Impact factor: 3.756

4.  Patent ductus arteriosus therapy: impact on neonatal and 18-month outcome.

Authors:  Juliette C Madan; Douglas Kendrick; James I Hagadorn; Ivan D Frantz
Journal:  Pediatrics       Date:  2009-02       Impact factor: 7.124

5.  Developmental and neuropathological consequences of ductal ligation in the preterm baboon.

Authors:  Michelle Loeliger; Terrie E Inder; Penelope A Dalitz; Sarah Cain; Emily J Camm; Bradley Yoder; Donald McCurnin; Phillip W Shaul; Ronald Clyman; Sandra M Rees
Journal:  Pediatr Res       Date:  2009-02       Impact factor: 3.756

6.  Outcomes of Early Ligation of Patent Ductus Arteriosus in Preterms, Multicenter Experience.

Authors:  Mohamed H Ibrahim; Ahmed A Azab; Naglaa M Kamal; Mostafa A Salama; Hatem H Elshorbagy; Enas A A Abdallah; Abdulrahman Hammad; Laila M Sherief
Journal:  Medicine (Baltimore)       Date:  2015-06       Impact factor: 1.889

7.  The timing of surgical ligation for patent ductus arteriosus is associated with neonatal morbidity in extremely preterm infants born at 23-25 weeks of gestation.

Authors:  Se In Sung; Soo Young Choi; Jae Hyun Park; Myung Sook Lee; Hye Soo Yoo; So Yoon Ahn; Yun Sil Chang; Won Soon Park
Journal:  J Korean Med Sci       Date:  2014-04-01       Impact factor: 2.153

8.  Neonatal Patent Ductus Arteriosus Ligation Operations Performed by Adult Cardiac Surgeons.

Authors:  Yoon Sang Chung; Dai Yun Cho; Hyun Kang; Na Mi Lee; Joonhwa Hong
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2017-08-05

9.  Outcome following surgical closure of patent ductus arteriosus in very low birth weight infants in neonatal intensive care unit.

Authors:  Ga Yeun Lee; Young Bae Sohn; Myo Jing Kim; Ga Won Jeon; Jae Won Shim; Yun Sil Chang; June Huh; I-Seok Kang; Ji-Hyuk Yang; Tae-Gook Jun; Pyo Won Park; Won Soon Park; Heung Jae Lee
Journal:  Yonsei Med J       Date:  2008-04-30       Impact factor: 2.759

10.  Outcomes of primary ligation of patent ductus arteriosus compared with secondary ligation after pharmacologic failure in very-low-birth-weight infants.

Authors:  Young-Ah Youn; Cheong-Jun Moon; So-Young Kim; Jae Young Lee; In-Kyung Sung
Journal:  Pediatr Cardiol       Date:  2013-12-27       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.